Beyond GLP-1: The Next Wave of Obesity Drugs

Dr. James Whitfield

[calm] Welcome to the show. Elena, I want to start with one head-to-head number: in SURMOUNT-5, tirzepatide produced about 20.2% mean weight loss versus 13.7% with semaglutide at 72 weeks. That gap matters because it tells us the field is no longer just tuning one GLP-1 knob.

Dr. Elena Rodriguez

[curious] Wait -- 20.2 versus 13.7. That's not a rounding-error difference; that's a different biologic strategy showing up in real patients. And tirzepatide is the proof point here because it's not pure GLP-1, it's GLP-1 plus GIP.

Dr. James Whitfield

Exactly. Semaglutide is a GLP-1 receptor agonist. In plain English, GLP-1 slows gastric emptying, reduces appetite, and improves glucose-dependent insulin secretion, so patients feel full sooner, eat less, and often see better glycemic control. Clinically, that's why we see both weight loss and lower A1c.

Dr. Elena Rodriguez

[thoughtful] And GIP is where people sometimes get lost, because the name sounds obscure. But mechanistically, GIP is another incretin hormone. Pairing it with GLP-1 seems to amplify satiety and improve how nutrients are handled after a meal. Well, not exactly amplify in every tissue -- more like complement. You're recruiting another signaling pathway rather than asking GLP-1 to do everything by itself.

Dr. James Whitfield

[matter-of-fact] Right, and that distinction matters. Tirzepatide's clinical effect is what made the rest of the pipeline credible. Once a dual agonist beats semaglutide in a direct trial, developers naturally ask: what if you add a third lever?

Dr. Elena Rodriguez

That third lever is often glucagon, which sounds backwards because clinicians hear glucagon and think, hold on, the hormone that raises glucose? But in this setting the idea is controlled agonism. Glucagon signaling may increase energy expenditure, alter lipid handling, and potentially deepen weight loss when balanced against GLP-1 and sometimes GIP. It's a three-pedal system, not one accelerator jammed to the floor.

Dr. James Whitfield

[skeptical] And we should be careful there. Mechanism is not outcome. The history of obesity pharmacotherapy is full of elegant ideas that did not become usable medicines. What changed the tone of the conversation was data: semaglutide set a modern benchmark, then tirzepatide moved that benchmark again.

Dr. Elena Rodriguez

[responds quickly] And now the early multi-agonist data are pushing even further. Retatrutide, which hits GLP-1, GIP, and glucagon receptors, showed phase 2 weight-loss signals approaching 24% at 48 weeks in obesity. Twenty-four percent is the kind of number that makes people compare drugs with bariatric surgery, and I think we have to slow that comparison down -- but it's why the pipeline feels different now.

Dr. James Whitfield

Yes. The comparison gets attention, but trial context matters. Different populations, different durations, different stopping rules. Also, 48 weeks is not five years. For clinicians, the practical point is narrower: these are not interchangeable versions of the same drug class. Semaglutide and tirzepatide already differ meaningfully in efficacy, tolerability patterns, and dose escalation. The next wave may diverge even more.

Dr. Elena Rodriguez

[reflective] I think that's the conceptual shift. We used to say, sort of casually, “the GLP-1s.” Increasingly that phrase is too blunt. We're looking at an incretin and multi-agonist era, where appetite, gastric emptying, insulin secretion, energy expenditure, maybe even liver fat biology, are being manipulated in combinations. The question isn't just how much weight comes off. It's which pathways give enough extra benefit to justify extra complexity, cost, and adverse effects.

Dr. James Whitfield

And that takes us straight to outcomes, because better weight-loss percentages are important -- but not sufficient.

Dr. Elena Rodriguez

[calm] Right. The field is broadening from “does it lower weight?” to “what else does that weight loss buy us?” We've now got a widening list of obesity-related indications and outcome signals: obstructive sleep apnea with tirzepatide in SURMOUNT-OSA, chronic kidney disease outcomes with semaglutide in FLOW, and MASH programs across this broader drug family that suggest liver disease may become a major use case.

Dr. James Whitfield

[questioning tone] Let me grab SURMOUNT-OSA, because that's a very concrete one. In adults with obesity and moderate-to-severe OSA, tirzepatide reduced the apnea-hypopnea index substantially -- not just a few events per hour, but clinically meaningful drops alongside major weight loss. That's the kind of result that changes how a pulmonologist and an internist talk to the same patient.

Dr. Elena Rodriguez

[genuinely surprised] Exactly. And for cardiovascular disease, semaglutide has the cleanest obesity-specific outcomes signal so far from SELECT: fewer major adverse cardiovascular events in patients with overweight or obesity and established cardiovascular disease, without diabetes. Tirzepatide's cardiovascular story is promising, especially in diabetes populations, but it still has to be interpreted in the context of comparator choice and where the full dedicated outcomes evidence lands. So I would not oversimplify that into “class effect, case closed.”

Dr. James Whitfield

[skeptical] I'm glad you said comparator choice. That's the trap. A positive signal against placebo tells one story; a result against dulaglutide or another active agent tells another. Clinicians need to ask, benefit compared with WHAT, in WHICH population, over HOW long?

Dr. Elena Rodriguez

And meanwhile the pipeline is getting crowded. Orforglipron is a small-molecule oral GLP-1 receptor agonist, which matters because an effective oral option could change access and uptake. Amycretin combines GLP-1 activity with amylin biology, another satiety pathway. Retatrutide is the flashy triple agonist. The numbers are eye-catching, yes, but many of these programs are still early or mid-stage. A dramatic phase 1 or phase 2 signal is not the same as mature safety and durability data.

Dr. James Whitfield

[matter-of-fact] Durability is the key word. We already know from semaglutide withdrawal data that stopping therapy often leads to substantial weight regain. So when patients ask, “Do I take this for a year?” the honest answer may be, “Maybe this is chronic therapy,” which has huge implications for cost, adherence, and equity.

Dr. Elena Rodriguez

And tolerability. GI adverse effects are common across the category -- nausea, vomiting, diarrhea, constipation. Then there are the rarer but very real concerns: gallbladder disease, pancreatitis questions, possible lean-mass loss if weight drops quickly without resistance training and adequate protein, and whatever uncommon signals only appear when millions of people use these drugs for years.

Dr. James Whitfield

[short pause] Plus the access mess. Coverage is inconsistent. Cash prices are high. Compounding has filled part of the demand gap, but quality and oversight are uneven, especially when products are marketed beyond well-regulated channels. That's not a side issue; that's the clinical environment these prescriptions enter.

Dr. Elena Rodriguez

The 24% retatrutide number, or the convenience promise of orforglipron, can make it sound like we're headed toward effortless treatment for a vast population. Maybe. But if long-term therapy is needed, if adverse effects limit escalation, and if insurance still treats obesity care as optional, then the science can outrun the system very quickly.

Dr. James Whitfield

[reflective] Which leaves us with a harder question than “which drug works best?” It might be: what level of evidence, safety follow-up, and affordability do we need before we normalize chronic multi-agonist treatment for tens of millions of people? I'm Dr. James Whitfield.

Dr. Elena Rodriguez

And I'm Dr. Elena Rodriguez. [softly] That's the part of this story still being written.